Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)
Comments